POINT Biopharma Global (PNT) Stock Price, News & Analysis

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNT, but not buy additional shares or sell existing shares.
View PNT analyst ratings or view top-rated stocks.

10 analysts have issued 12-month target prices for POINT Biopharma Global's stock. Their PNT share price targets range from $12.50 to $14.00. On average, they predict the company's share price to reach $12.80 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for PNT or view top-rated stocks among Wall Street analysts.

POINT Biopharma Global Inc. (NASDAQ:PNT) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07. The firm earned $2.79 million during the quarter, compared to analysts' expectations of $8 million. POINT Biopharma Global had a net margin of 39.62% and a trailing twelve-month return on equity of 21.10%.